Bio-Thera Solutions, Ltd.'s (SHSE:688177) Last Week's 8.7% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Bio-Thera Solutions, Ltd.'s (SHSE:688177) Last Week's 8.7% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Key Insights
主要见解
- The considerable ownership by private companies in Bio-Thera Solutions indicates that they collectively have a greater say in management and business strategy
- The top 2 shareholders own 52% of the company
- 18% of Bio-Thera Solutions is held by insiders
- 私人公司在Bio-Thera Solutions拥有的相当大股权表明它们共同在管理和业务策略上拥有更大的发言权
- 前2名股东拥有该公司的52%。
- Bio-Thera Solutions有18%的股份由内部持有人持有
A look at the shareholders of Bio-Thera Solutions, Ltd. (SHSE:688177) can tell us which group is most powerful. With 51% stake, private companies possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
查看Bio-Thera Solutions有限公司(SHSE:688177)的股东情况,可以告诉我们哪个群体最有权势。私人公司持有51%的股份,是公司中持股最多的。换句话说,该群体有可能因对公司的投资而获益最大(或损失最大)
While insiders, who own 18% shares weren't spared from last week's CN¥903m market cap drop, private companies as a group suffered the maximum losses
尽管拥有18%股份的内部人士没有幸免于上周人民币90300万市值的下跌,但私营公司作为一个整体遭受了最大的损失
Let's delve deeper into each type of owner of Bio-Thera Solutions, beginning with the chart below.
让我们深入了解Bio-Thera Solutions的每类所有者,首先从下面的图表开始。
What Does The Institutional Ownership Tell Us About Bio-Thera Solutions?
从机构持股情况可以看出Bio-Thera Solutions的情况如何?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
机构投资者通常将自己的回报与常见的指数回报进行比较。因此,他们通常会考虑购买包括在相关基准指数中的较大公司。
Bio-Thera Solutions already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Bio-Thera Solutions' earnings history below. Of course, the future is what really matters.
Bio-Thera Solutions的股份登记表上已经有一些机构。事实上,他们在该公司拥有可观的股份。 这意味着为这些机构工作的分析师已经研究过这支股票,而且他们喜欢它。 但和其他人一样,他们也可能出错。 如果多家机构同时改变对一支股票的看法,股价可能会迅速下降。 因此,值得看一下Bio-Thera Solutions在下面的收益历史。 当然,未来才是真正重要的。
Hedge funds don't have many shares in Bio-Thera Solutions. Guangzho Hedy Group Co., Ltd. is currently the largest shareholder, with 39% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 13% and 5.6%, of the shares outstanding, respectively. Shengfeng Li, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.
对比特拉方案,对冲基金持有的股份不多。广州合地集团有限公司目前是最大的股东,持有39%的流通股。同时,第二大和第三大股东分别持有流通股的13%和5.6%。第二大股东李胜峰也恰好担任首席执行官。
A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 52% stake.
国瑞科技有合理比例的内部所有权。内部人士在这家市值为人民币18亿元的公司中拥有4.27亿元的股份。这可能表明创始人仍然拥有很多股份。您可以单击此处查看他们是否一直在买卖。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
虽然研究一个公司的机构持股数据是有意义的,但研究分析师预期增长也是有意义的,因为很多分析师都有关注这些股票,因此可以很容易地了解预期增长。
Insider Ownership Of Bio-Thera Solutions
Bio-Thera Solutions的内部所有权
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
在不同国家,内部人员的定义可能会略有不同,但董事会成员始终是内部人员。管理层最终向董事会负责。然而,如果管理人员是创始人或CEO,那么成为执行董事会成员也是很常见的。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多数人认为内部所有权是积极的,因为它可以表示董事会与其他股东的利益相一致。但是,在某些场合下,这个团体的权力过于集中。
Our information suggests that insiders maintain a significant holding in Bio-Thera Solutions, Ltd.. It has a market capitalization of just CN¥9.5b, and insiders have CN¥1.7b worth of shares in their own names. That's quite significant. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
我们的信息显示,内部人士在Bio-Thera Solutions, Ltd.持有大量股份。市值仅为95亿元人民币,内部人士自己名下拥有17亿元人民币的股票。这相当可观。看到这种投资水平是件好事。您可以在这里查看这些内部人士最近是否一直在买入。
General Public Ownership
一般大众所有权
The general public, who are usually individual investors, hold a 13% stake in Bio-Thera Solutions. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
普通大众,通常是个体投资者,在Bio-Thera Solutions持有13%的股份。虽然这个群体通常无法左右决策,但确实可以对公司的运营产生实质影响。
Private Equity Ownership
股权投资公司持有8.8%的股份,有能力参与塑造以价值创造为重点的公司策略。一些投资者可能会因此而受到鼓舞,因为股权投资公司有时可以鼓励市场看到公司的价值,从而采取有益的策略。另外,那些持有者可能在将其上市后退出投资。
With an ownership of 5.2%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
作为业务价值创造的焦点,股权投资公司以5.2%的所有权在塑造企业策略中扮演着重要角色。一些投资者可能会因此感到鼓舞,因为股权投资有时能够推动帮助市场认识到公司价值的策略。或者,这些股东们可能在将公司上市后退出了投资。
Private Company Ownership
私有公司的所有权
We can see that Private Companies own 51%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
虽然考虑到拥有公司的不同团体确实很值得思考,但还有更重要的因素。事实证明,我们发现了一条有关国邦制药的警告信息,您应该注意。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important.
虽然考虑所有拥有一家公司的群体很重要,但还有其他更重要的因素。
I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.
我喜欢深入了解一家公司过去的表现。您可以免费访问该互动图表,了解其过去的盈利、营业收入和现金流。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果您像我一样,可能希望考虑这家公司是否会增长或缩小。幸运的是,您可以查看此免费报告,显示分析师对其未来的预测。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。